Insider Buy/Sell Details for the Biotechnology Industry — Last 3 Months
Ratio0.1:1
Daily Buy & Sell Volume
Transactions (3462)
UNITED THERAPEUTICS Corp (UTHR)
MALCOLM JAN — Director
Shares
50
Price
$474.23
Total Value
$23.71K
Shares Held After
270
% of Holdings
15.6%
Spero Therapeutics, Inc. (SPRO)
Keutzer Timothy — Chief Operating Officer
Shares
18,891
Price
$2.20
Total Value
$41.56K
Shares Held After
788,853
% of Holdings
2.3%
Spero Therapeutics, Inc. (SPRO)
Rajavelu Esther — Chief Executive Officer, Chief Financial Officer and Chief Business Officer
Shares
18,442
Price
$2.20
Total Value
$40.57K
Shares Held After
1,100,008
% of Holdings
1.6%
MapLight Therapeutics, Inc. (MPLT)
Malenka Robert C. — Director
Shares
7,039
Price
$18.02
Total Value
$126.84K
Shares Held After
358,234
% of Holdings
1.9%
Spyre Therapeutics, Inc. (SYRE)
Turtle Cameron — Director
Shares
14,043
Price
$32.87
Total Value
$461.59K
Shares Held After
657,540
% of Holdings
2.1%
Spyre Therapeutics, Inc. (SYRE)
Turtle Cameron — Director
Shares
957
Price
$31.82
Total Value
$30.45K
Shares Held After
671,583
% of Holdings
0.1%
Zentalis Pharmaceuticals, Inc. (ZNTL)
Vultaggio Vincent — PAO and PFO
Shares
2,540
Price
$2.55
Total Value
$6.48K
Shares Held After
187,286
% of Holdings
1.3%
OCULAR THERAPEUTIX, INC (OCUL)
Notman Donald — Chief Operating Officer
Shares
5,455
Price
$9.14
Total Value
$49.86K
Shares Held After
383,837
% of Holdings
1.4%
Arcutis Biotherapeutics, Inc. (ARQT)
Matsuda Masaru — Reporting Person's title: SVP General Counsel and Corporate Secretary
Shares
4,714
Price
$25.63
Total Value
$120.82K
Shares Held After
110,003
% of Holdings
4.1%
Arcutis Biotherapeutics, Inc. (ARQT)
Matsuda Masaru — Reporting Person's title: SVP General Counsel and Corporate Secretary
Shares
19,379
Price
$25.24
Total Value
$489.13K
Shares Held After
114,717
% of Holdings
14.5%
Arcutis Biotherapeutics, Inc. (ARQT)
Matsuda Masaru — Reporting Person's title: SVP General Counsel and Corporate Secretary
Shares
8,562
Price
$24.97
Total Value
$213.79K
Shares Held After
134,096
% of Holdings
6.0%
Arcutis Biotherapeutics, Inc. (ARQT)
Matsuda Masaru — Reporting Person's title: SVP General Counsel and Corporate Secretary
Shares
7,983
Price
$25.50
Total Value
$203.55K
Shares Held After
142,658
% of Holdings
5.3%
Sionna Therapeutics, Inc. (SION)
Thompson Peter A. — Director
Shares
1,890
Price
$44.57
Total Value
$84.24K
Shares Held After
3,559,765
% of Holdings
0.1%
Adaptive Biotechnologies Corp (ADPT)
ROBINS HARLAN S — Chief Scientific Officer
Shares
34,668
Price
$18.60
Total Value
$644.82K
Shares Held After
1,187,644
% of Holdings
2.8%
Apogee Therapeutics, Inc. (APGE)
Henderson Jane — Chief Financial Officer
Shares
100
Price
$66.89
Total Value
$6.69K
Shares Held After
183,371
% of Holdings
0.1%
Apogee Therapeutics, Inc. (APGE)
Henderson Jane — Chief Financial Officer
Shares
1,108
Price
$66.15
Total Value
$73.29K
Shares Held After
183,471
% of Holdings
0.6%
Apogee Therapeutics, Inc. (APGE)
Henderson Jane — Chief Financial Officer
Shares
792
Price
$65.21
Total Value
$51.65K
Shares Held After
184,579
% of Holdings
0.4%
Arcutis Biotherapeutics, Inc. (ARQT)
Vairavan Latha — SVP Chief Financial Officer
Shares
1,320
Price
$25.50
Total Value
$33.66K
Shares Held After
63,607
% of Holdings
2.0%
Arcutis Biotherapeutics, Inc. (ARQT)
Edwards Larry Todd — Reporting Person's title: EVP Chief Commercial Officer
Shares
2,052
Price
$25.50
Total Value
$52.32K
Shares Held After
148,865
% of Holdings
1.4%
Arcutis Biotherapeutics, Inc. (ARQT)
Welgus Howard G. — Director
Shares
10,000
Price
$25.05
Total Value
$250.48K
Shares Held After
59,744
% of Holdings
14.3%
Arcutis Biotherapeutics, Inc. (ARQT)
Watanabe Todd — Director
Shares
19,833
Price
$25.50
Total Value
$505.71K
Shares Held After
721,306
% of Holdings
2.7%
Arcutis Biotherapeutics, Inc. (ARQT)
Burnett Patrick — Reporting Person's Title: Executive Vice President and Chief Medical Officer
Shares
3,675
Price
$25.50
Total Value
$93.71K
Shares Held After
90,445
% of Holdings
3.9%
Adaptive Biotechnologies Corp (ADPT)
ROBINS CHAD M — Director
Shares
124,998
Price
$18.44
Total Value
$2.30M
Shares Held After
2,459,245
% of Holdings
4.8%
Sionna Therapeutics, Inc. (SION)
ORBIMED ADVISORS LLC — Director
Shares
1,890
Price
$44.57
Total Value
$84.24K
Shares Held After
3,559,765
% of Holdings
0.1%
Kiniksa Pharmaceuticals International, plc (KNSA)
Quart Barry D — Director
Shares
830
Price
$45.00
Total Value
$37.35K
Shares Held After
12,546
% of Holdings
6.2%
Allogene Therapeutics, Inc. (ALLO)
Parker Geoffrey M. — CHIEF FINANCIAL OFFICER
Shares
24,001
Price
$1.76
Total Value
$42.24K
Shares Held After
1,252,795
% of Holdings
1.9%
Allogene Therapeutics, Inc. (ALLO)
Chang David D — Director
Shares
95,269
Price
$1.80
Total Value
$171.48K
Shares Held After
5,185,862
% of Holdings
1.8%
LIGAND PHARMACEUTICALS INC (LGND)
KOZARICH JOHN W — Director
Shares
23
Price
$197.19
Total Value
$4.54K
Shares Held After
43,187
% of Holdings
0.1%
LIGAND PHARMACEUTICALS INC (LGND)
KOZARICH JOHN W — Director
Shares
381
Price
$196.36
Total Value
$74.81K
Shares Held After
43,210
% of Holdings
0.9%
LIGAND PHARMACEUTICALS INC (LGND)
KOZARICH JOHN W — Director
Shares
23
Price
$195.60
Total Value
$4.50K
Shares Held After
43,591
% of Holdings
0.1%
LIGAND PHARMACEUTICALS INC (LGND)
KOZARICH JOHN W — Director
Shares
1
Price
$192.18
Total Value
$192.18
Shares Held After
43,614
% of Holdings
0.0%
LIGAND PHARMACEUTICALS INC (LGND)
KOZARICH JOHN W — Director
Shares
39
Price
$191.00
Total Value
$7.45K
Shares Held After
43,615
% of Holdings
0.1%
Allogene Therapeutics, Inc. (ALLO)
Beneski Benjamin Machinas — SVP, Chief Technical Officer
Shares
7,549
Price
$1.73
Total Value
$13.06K
Shares Held After
210,172
% of Holdings
3.5%
Maze Therapeutics, Inc. (MAZE)
Bachrodt Amy — SVP, Finance
Shares
736
Price
$46.63
Total Value
$34.32K
Shares Held After
12,965
% of Holdings
5.4%
Maze Therapeutics, Inc. (MAZE)
Bachrodt Amy — SVP, Finance
Shares
4,064
Price
$46.03
Total Value
$187.07K
Shares Held After
13,701
% of Holdings
22.9%
Maze Therapeutics, Inc. (MAZE)
Bachrodt Amy — SVP, Finance
Shares
200
Price
$44.15
Total Value
$8.83K
Shares Held After
17,765
% of Holdings
1.1%
LEXICON PHARMACEUTICALS, INC. (LXRX)
Invus Global Management, LLC — Director
Shares
1,538,462
Price
$1.30
Total Value
$2.00M
Shares Held After
1,538,462
% of Holdings
100.0%
Maze Therapeutics, Inc. (MAZE)
Bernstein Harold — President, R&D & CMO
Shares
100
Price
$47.23
Total Value
$4.72K
Shares Held After
0
% of Holdings
100.0%
Maze Therapeutics, Inc. (MAZE)
Bernstein Harold — President, R&D & CMO
Shares
5,936
Price
$46.37
Total Value
$275.27K
Shares Held After
100
% of Holdings
98.3%
Maze Therapeutics, Inc. (MAZE)
Bernstein Harold — President, R&D & CMO
Shares
8,364
Price
$45.89
Total Value
$383.82K
Shares Held After
6,036
% of Holdings
58.1%
Maze Therapeutics, Inc. (MAZE)
Bernstein Harold — President, R&D & CMO
Shares
600
Price
$44.20
Total Value
$26.52K
Shares Held After
14,400
% of Holdings
4.0%
ABEONA THERAPEUTICS INC. (ABEO)
Silverstein Christine Berni — Director
Shares
20,070
Price
$5.09
Total Value
$102.17K
Shares Held After
137,722
% of Holdings
12.7%
Absci Corp (ABSI)
Jonasson Zachariah — CFO / CBO
Shares
17,496
Price
$2.99
Total Value
$52.31K
Shares Held After
383,538
% of Holdings
4.4%
Absci Corp (ABSI)
McClain Sean — Director
Shares
26,761
Price
$2.99
Total Value
$80.02K
Shares Held After
8,334,567
% of Holdings
0.3%
Allogene Therapeutics, Inc. (ALLO)
Roberts Zachary — EVP of R&D
Shares
35,700
Price
$1.77
Total Value
$63.19K
Shares Held After
581,166
% of Holdings
5.8%
Royalty Pharma plc (RPRX)
Coyne Terrance P. — EVP & CFO
Shares
5,843
Price
$42.08
Total Value
$245.90K
Shares Held After
30,167
% of Holdings
16.2%
Royalty Pharma plc (RPRX)
Coyne Terrance P. — EVP & CFO
Shares
102,581
Price
$42.08
Total Value
$4.32M
Shares Held After
292,415
% of Holdings
26.0%
Allogene Therapeutics, Inc. (ALLO)
Yoshiyama Annie — SVP, Finance
Shares
4,167
Price
$1.72
Total Value
$7.17K
Shares Held After
130,322
% of Holdings
3.1%
Allogene Therapeutics, Inc. (ALLO)
Douglas Earl Martin — SVP, General Counsel
Shares
22,900
Price
$1.76
Total Value
$40.30K
Shares Held After
564,948
% of Holdings
3.9%
Amylyx Pharmaceuticals, Inc. (AMLX)
Klee Justin B. — Director
Shares
15,500
Price
$14.69
Total Value
$227.62K
Shares Held After
3,363,898
% of Holdings
0.5%
Showing 2751–2800 of 3462 transactions (page 56 of 70)